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Abstract
Background: Nitric oxide (NO) plays a role in a number of physiological processes including stem cell differentiation
and osteogenesis. Endothelial nitric oxide synthase (eNOS), one of three NO-producing enzymes, is located in a close
conformation with the caveolin-1 (CAV-1WT) membrane protein which is inhibitory to NO production. Modification of
this interaction through mutation of the caveolin scaffold domain can increase NO release. In this study, we genetically
modified equine adipose-derived stem cells (eASCs) with eNOS, CAV-1WT, and a CAV-1F92A (CAV-1WT mutant) and
assessed NO-mediated osteogenic differentiation and the relationship with the Wnt signaling pathway.
Methods: NO production was enhanced by lentiviral vector co-delivery of eNOS and CAV-1F92A to eASCs, and
osteogenesis and Wnt signaling was assessed by gene expression analysis and activity of a novel Runx2-GFP reporter.
Cells were also exposed to a NO donor (NONOate) and the eNOS inhibitor, L-NAME.
Results: NO production as measured by nitrite was significantly increased in eNOS and CAV-1F92A transduced eASCs
+(5.59 ± 0.22 μM) compared to eNOS alone (4.81 ± 0.59 μM) and un-transduced control cells (0.91 ± 0.23 μM) (p < 0.05).
During osteogenic differentiation, higher NO correlated with increased calcium deposition, Runx2, and alkaline
phosphatase (ALP) gene expression and the activity of a Runx2-eGFP reporter. Co-expression of eNOS and CAV-1WT
transgenes resulted in lower NO production. Canonical Wnt signaling pathway-associated Wnt3a and Wnt8a gene
expressions were increased in eNOS-CAV-1F92A cells undergoing osteogenesis whilst non-canonical Wnt5a was
decreased and similar results were seen with NONOate treatment. Treatment of osteogenic cultures with 2 mM L-
NAME resulted in reduced Runx2, ALP, and Wnt3a expressions, whilst Wnt5a expression was increased in eNOS-
delivered cells. Co-transduction of eASCs with a Wnt pathway responsive lenti-TCF/LEF-dGFP reporter only showed
activity in osteogenic cultures co-transduced with a doxycycline inducible eNOS. Lentiviral vector expression of
canonical Wnt3a and non-canonical Wnt5a in eASCs was associated with induced and suppressed osteogenic
differentiation, respectively, whilst treatment of eNOS-osteogenic cells with the Wnt inhibitor Dkk-1 significantly
reduced expressions of Runx2 and ALP.
Conclusions: This study identifies NO as a regulator of canonical Wnt/β-catenin signaling to promote osteogenesis in
eASCs which may contribute to novel bone regeneration strategies.
* Correspondence: pstrappe@csu.edu.au; padraigstrappe@hotmail.com
1School of Biomedical Sciences, Charles Sturt University, Wagga Wagga, NSW
2650, Australia
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Bandara et al. Stem Cell Research & Therapy  (2016) 7:182 
DOI 10.1186/s13287-016-0442-9
Background
Mesenchymal stem cells (MSCs) have been isolated from
various tissues such as adipose [1], heart [2], bone mar-
row [3, 4], and blood [5–9], and have the potential to
differentiate into different lineages, including osteoblasts,
chondrocytes, and adipocytes [10, 11]. The osteoblast
differentiation program of MSCs is switched on by cell
recruitment, and timely expression of genes including
Runx2, alkaline phosphatase (ALP), type I collagen
(ColA1), and osteocalcin (OC) followed by extracellular
matrix mineralization [12]. This process can be induced
by soluble molecules such as bone morphogenetic pro-
teins (BMPs) [13] or Wnts [14–16] that activate several
pathways and other various downstream signals such as
protein kinase [17] and growth factors [18] to trigger
osteoblast differentiation of mesenchymal stem cells.
Nitric oxide (NO) is a signaling molecule with a short
half-life [19, 20]. It can react within the cell where it is
produced or penetrate cell membranes to affect adjacent
cells [21]. NO exerts a variety of physiological effects such
as regulating blood pressure via smooth muscle relaxation
[22], mediating immune responses [23], controlling cell
proliferation [24], modulating apoptosis [20], promoting
growth factor-induced angiogenesis [4, 21], accelerating
wound healing [4, 25], and functioning as a neurotrans-
mitter [26]. These responses can be mediated through
activating the primary NO effector soluble guanylyl
cyclase to produce cGMP [27] by NO-based chemical
modifications of proteins through S-nitrosylation [28] or
through epigenetic modification [29]. NO is known to play
an important role in bone homeostasis. It is generated by
many cell types present in the bone environment, most
notably the osteoblast [30].
NO is synthesized from L-arginine by three isozymes of
nitric oxide synthase (NOS), including neuronal NOS
(nNOS), endothelial NOS (eNOS), and cytokine-inducible
NOS (iNOS) [31]. Both iNOS [32, 33] and eNOS [34] have
been shown to play a role in osteoblast differentiation.
Mice lacking eNOS have shown marked bone abnormal-
ities due to impaired osteoblast differentiation resulting in
poor maintenance of bone mass [35, 36]. Gene expression
data from neonatal calvarial osteoblasts from eNOS–/–
mice have shown downregulation of Runx2, Cbfa-1, and
osteocalcin [37]. On the other hand, high concentrations
of NO released due to the pathological iNOS expression
promote bone resorption through induced osteoclastogen-
esis [38]. Therefore, an optimum level of NO is important
to drive osteogenic differentiation of the MSCs.
In contrast with other NOS family members, eNOS is
localized mainly in specific intracellular membrane do-
mains, including the Golgi apparatus [39] and plasma
membrane caveolae [40, 41]. A previously demonstrated
direct interaction of eNOS with wild-type caveolin-1
(CAV-1WT) [42] has proposed that CAV-1WT functions
as an endogenous negative regulator of eNOS [43]. In this
context, eNOS binds to the caveolin-1 scaffolding domain
(CSD; amino acids 82–101) [44] and, furthermore, Thr-90
and Thr-91 (T90 and T91), and Phe-92 (F92) were identi-
fied as critical residues for eNOS binding and inhibition
[41]. Genetic modification of endothelial cells through
overexpression of a mutated version of CAV-1 with a
phenylalanine to alanine substitution at the amino acid
position 92 (CAV-1F92A) resulted in increased NO produc-
tion, overcoming the inhibitory effect of CAV-1WT [41].
In the present study, we tested the hypothesis that mo-
lecular control of NO synthesis in equine adipose-
derived stem cells (eASCs), can promote osteogenic dif-
ferentiation where endogenous eNOS is not available, by
recreating the interaction between eNOS and CAV-1
(CAV-1WT and CAV-1F92A) regulates the osteogenic dif-
ferentiation of eASCs. Our results indicate that the
optimum level of NO induces osteogenic differentiation




eASCs were isolated from subcutaneous adipose tissue
as previously described [45]. All sampling was carried
out using protocols approved by the Charles Sturt Uni-
versity Animal Care and Ethics Committee. Human em-
bryonic kidney 293 T cells (HEK293T) (ATCC, VA,
USA) and eASCs were cultured and maintained in Dul-
becco’s modified Eagle’s medium (DMEM; Sigma-
Aldrich, MO, USA) supplemented with 10% (v/v) fetal
bovine serum (FBS; Bovogen, VIC, Australia), 100 U/mL
penicillin, 100 μg/mL streptomycin, and 2 mM L-glutam-
ine (Invitrogen) (growth medium) at 37 °C and 5% CO2.
Plasmid constructs
The list of cDNA for the genes of interest used in this study
is listed in Table 1, and was used for construction of lenti-
viral vectors. HF Phusion (New England Biolabs; NEB)
DNA polymerase was used for all the polymerase chain
Table 1 Lentiviral vectors and reporter constructs used in this
study
Lentiviral vector Relevant properties Source or reference
pWPT-eNOS CMV-eNOS This study
FUW-eNOS TetO-eNOS This study
pWPT-CAV-1F92A CMV-CAV-1F92A This study and [41]
pLVX-CAV-1WT CMV-CAV-1WT This study
pTRIP-Runx2.Hsp68-eGFP Runx2.Hsp68-eGFP This study and [46]
pLX304-Wnt3a CMV-Wnt3a DNASU (HsCD00436739)
pLX304-Wnt5a CMV-Wnt5a DNASU (HsCD00442542)
pRRL-TCF/LEF-GFP TCF/LEF-dGFP Addgene (#14715)
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reactions (PCRs) and all the restriction endonucleases were
purchased from NEB unless indicated otherwise.
To construct the CMV promoter-driven eNOS express-
ing lentiviral vector, a codon optimized eNOS gene was
synthesized [4] and subcloned into the pWPT-GFP
lentiviral plasmid (Addgene, MA, USA) using BamH1 and
Sal1 restriction endonucleases. Doxycycline (DOX) indu-
cible eNOS construct was prepared by amplifying the
eNOS gene using the forward (ATCAGAATTCATGGG-
CAACCTGAA) and reverse primer (ATCAGAATTCT-
CATCAGGGGCTGT) by introducing EcoR1 restriction
sites (underlined sequences in both forward and reverse
primers) at both the 5’ and 3’ ends of the final PCR prod-
uct, followed by subcloning the PCR product into FUW-
TetO vector (Addgene). Human wild-type caveolin-1
(CAV-1WT) expressing lentiviral vector was constructed
by inserting the full length CAV-1WT (Addgene) into
pLVX-AcGFP1-C1 and pLVX-DsRed-C1 (Clontech, CA,
USA) using EcoR1 and BamH1 restriction endonucleases.
A mutated caveolin-1 (CAV-1F92A) in which phenylalanine
(F) at the amino acid position 92 was replaced with
alanine (A) [41] was synthesized (Geneart), amplified by
PCR by introducing BamH1 and Sal1 sites at the 5’ and 3’
ends of the PCR product, respectively, via forward primer
(ATCAGGATCCATGTCTGGGGGCA) and reverse pri-
mer (ATCAGTCGACTTATATTTCTTTCTG) (restric-
tion sites are underlined). The PCR product was then
ligated into the pWPT-GFP lentiviral vector (Addgene) at
the BamH1 and Sal1 restriction sites replacing GFP.
Wnt3a and Wnt5a expressing lentiviral plasmids were
purchased from DNAsu plasmid repository.
GFP reporter constructs
A 343‐bp fragment of the Runx2 enhancer region (sequence
information was kindly provided by Toshihisa Komori at the
Department of Cell Biology, Nagasaki University) [46] was
synthesized together with the sequence of the Hsp68 min-
imal promoter (GenScript, NJ, USA). The entire fragment
was then subcloned into pTRIP-eGFP lentiviral vector at the
Mlu1 and BamH1 restriction sites replacing an insulin-
specific promoter, upstream of the enhanced GFP (eGFP)
coding sequence. The Wnt responsive lentiviral TCF/LEF-
dGFP reporter system was purchased from Addgene.
Lentiviral vector production and transduction of equine
adipose stem cells
Lentiviral vectors used in this study (Table 1) were gener-
ated by four plasmid transfection of HEK293T cells. Briefly,
each well of a six-well tissue culture plate was coated with
50 μg/mL of DL-lysine (Sigma-Aldrich) in phosphate-
buffered saline (PBS) and incubated for 2 h at 37 °C.
HEK293Tcells were then seeded at a density of 1 × 106 cells
per well, 24 h prior to transfection of 6.3 μg of packaging
plasmid psPAX2 (Addgene), 3.1 μg of Rev expression
plasmid pRSV Rev (Addgene), 3.5 μg of VSV-G envelop
pMD2.G (Addgene), and 10 μg of the gene of interest
expression transfer vector using a standard calcium
phosphate transfection method [47]. Seventeen hours post-
transfection, the media was changed and supernatant
containing lentiviral vectors were collected at 48 h and 72 h
post-transfection, combined, and filtered through a 0.45-
μM PVDF filter, and used for eASC transduction in the
presence of 4 μg/mL Polybrene (Sigma-Aldrich).
Osteogenic differentiation
eASCs were seeded in a 12-well plate (11,000 cells/cm2) in
triplicate in growth medium overnight followed by trans-
duction with eNOS, CAV-1WT, and CAV-1F92A lentiviruses.
After 3 days, growth medium was replaced with osteogenic
induction medium (OM; growth medium+ 0.2 mM 2-
phospho-L-ascorbic acid trisodium salt + 10 nM dexametha-
sone + 10 mM β-glycerol phosphate; Sigma-Aldrich). Non-
induced control cells were cultured in growth medium.
Medium was changed every 3 days (see Fig. 2a below).
After 11 days incubation in OM or control growth
medium, cells were washed with PBS and fixed with 4%
(w/v) paraformaldehyde (Sigma-Aldrich) for 20 min,
washed with distilled water, and then stained with 2%
(w/v) Alizarin Red S (pH 4.2) for 20 min. Stained cells
were washed with distilled water prior to assessment by
light microscopy using a Nikon Eclipse Ti-S inverted
microscope (Nikon, Japan).
Alizarin Red S quantification
Quantification of Alizarin Red S staining was performed
as previously described [48]. Briefly, after staining the
cells with Alizarin Red S for 20 min, 10% acetic acid was
added to the 12-well cell culture plate and incubated for
30 min with shaking. The Alizarin Red S stain was ex-
tracted and the absorbance was measured at 405 nm in
parallel with Alizarin Red S standards comprising of ser-
ial 1:2 dilutions of 50 mM Alizarin Red S (pH 4.2).
Quantitative real-time PCR
Total RNA from transduced and control cells after 11 days
of incubation in OM or growth medium was isolated using
the PureZol reagent (Bio-Rad, CA, USA) according to the
manufacturer’s instructions, and the concentration of
isolated RNA was determined using a Nanodrop spectro-
photometer (Thermo Fisher Scientific), treated with RQ1
RNase free DNase (1 U/1 μg RNA; Promega, WI, USA).
cDNA was synthesized with 1 μg RNA from all samples
using a High Capacity Reverse Transcription Kit (Thermo
Fisher Scientific). Quantitative real-time PCR assays were
performed on a BioRad CFX96 Real-Time system (Bio-Rad)
using the SsoFast EvaGreen Supermix (Bio-Rad). Primer
sequences used for target gene amplification are described
in Table 2. Assays were performed in triplicate and target
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gene expression was normalized to equine β-actin mRNA
levels using the ΔΔCt method.
Immunocytochemistry and confocal microscopy
Immunocytochemical detection of eNOS and caveolin-1
(CAV-1WT and CAV-1F92A) expression in eASCs was
performed as follows. Briefly, cells were fixed in 4%
paraformaldehyde for 20 min at 37 °C, treated with 0.1%
Triton-X100 in PBS for 10 min, and blocked in a 10%
FBS in PBS solution for 30 min at room temperature.
This was followed by a 2-h incubation with a primary
mouse monoclonal anti-eNOS antibody (BD Biosciences,
CA, USA) or rabbit polyclonal anti-CAV-1 antibody
(Cell Signaling Technology, MA, USA), and subse-
quently with an anti-mouse IgG secondary antibody
conjugated with Alexa 488 (Cell Signaling Technology)
or anti-rabbit IgG secondary antibody conjugated with
Alexa 555 (Cell Signaling Technology) for 1 h and coun-
terstained with DAPI for nuclear staining (Sigma-Al-
drich). eNOS and CAV-1 co-localization was observed
by confocal microscopy (Nikon).
To detect β-catenin expression, eNOS transduced cells
(with or without DOX treatment) and un-transduced
cells were fixed in 4% paraformaldehyde for 20 min at
37 °C, treated with 0.1% Triton-X100 in PBS for 10 min,
and blocked in a 10% FBS in PBS solution for 30 min at
room temperature. This was followed by an overnight
incubation with a primary rabbit monoclonal anti-β-
catenin antibody (Cell Signaling Technology) and subse-
quently with an anti-rabbit IgG secondary antibody con-
jugated with Alexa 488 (Cell Signaling Technology) for
1 h and counterstained with DAPI.
GFP reporter assays
For GFP-based reporter assays for both TCF/LEF-dGFP
and Runx2.Hsp68-eGFP, cells transduced with the TCF/
LEF-dGFP and Runx2.Hsp68-eGFP were subjected for
reverse transcription quantitative PCR (RT-qPCR) for
GFP expression and fluorescence microscopic analysis,
respectively.
Nitric oxide detection
Extracellular NO production was measured using the
Griess reagent (Promega) according to the manufac-
turer’s instructions and measurement of absorbance at
540 nm. Triplicates of each sample were measured at
each time-point during osteogenic differentiation from
day 0 to day 11.
Statistical analysis
All experiments were performed in triplicate and at least
three times. Data are presented as mean ± SEM. The
statistical significances were determined by one-way ana-
lysis of variance (ANOVA) followed by Tukey’s test. All
tests were performed using the statistical software




eASCs were spindle-shaped and adherent to plastic tis-
sue culture dishes (data not shown). We have previously
reported their tri-linage differentiation potentials [49].
eNOS and caveolin-1 expression in eASCs
eNOS activation is controlled at the cell plasma membrane
significantly by CAV-1, a major structural protein in caveo-
lae [50, 51]. We investigated eNOS and CAV-1 expression
in un-transduced and transduced eASCs by immunofluor-
escence microscopy. Wild-type CAV-1 (CAV-1WT)-trans-
duced eASCs (eASCCAV-1WT) and un-transduced eASCs
(eASCWT) expressed CAV-1 protein; notably, the CAV-1
expression was increased in eASCCAV-1WT (Fig. 1d) com-
pared to eASCWT (Fig. 1c). Interestingly, eNOS expression
was absent in eASCWT (Fig. 1a), whereas strong eNOS ex-
pression was observed in eNOS-transduced cells (eASCe-
NOS) (Fig. 1b). Next, we examined the localization of eNOS,
CAV-1WT, and mutated CAV-1 (CAV-1F92A) in genetically
modified eASC by confocal microscopy. As expected,
eNOS expression was detected at the cytoplasm (Fig. 1e),
whereas both the CAV-1F92A (Fig. 1f) and CAV-1WT
(Fig. 1g) expressions were observed at the plasma mem-
brane, confirming that F92A mutation of CAV-1 does not
affect its cellular localization. Co-localization of eNOS and
CAV-1F92A in co-transduced eASCs with eNOS and CAV-
1F92A (eASCeNOS+CAV-1F92A) was examined by confocal mi-
croscopy with expression of eNOS in the cytoplasm and
CAV-1F92A at the plasma membrane (Fig. 1h). As controls
for primary antibodies, immunostaining was carried out in
Table 2 Primers used for reverse transcription quantitative
polymerase chain reaction
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the absence of primary antibodies specific to eNOS and
CAV-1 (Additional file 1: Figure S1).
NO enhances osteogenic differentiation
To examine the role of the NO signaling in eASCs
osteogenesis, we first compared the osteogenic differenti-
ation between eNOS transduced (eASCeNOS) and un-
transduced eASCs (eASCWT). A greater number of Ali-
zarin Red S-positive nodules were induced in the eASCe-
NOS cultures compared to eASCWT culture after 11 days
(Fig. 2b). NO synthesis was also significantly increased in
eASCeNOS compared to eASCWT (Fig. 2c). Quantification
of calcium deposition showed increased levels of calcium
deposition in eASCeNOS compared to eASCWT (Fig. 2d).
Quantitative analysis of Runx2 (Fig. 2e) and ALP (Fig. 2f)
gene expression were also significantly upregulated in the
eASCeNOS cultures compared to the eASCWT cultures.
NO-mediated osteogenic differentiation was further
highlighted by inhibition of eNOS activity. eASCeNOS
were treated with 2 mM of the nitric oxide synthase in-
hibitor, L-NG-nitroarginine methyl ester (L-NAME) for
11 days. L-NAME treatment resulted in a significant
downregulation of osteoblast-specific marker expres-
sions, ALP (Fig. 3a) and Runx2 (Fig. 3b), compared to
untreated eASCeNOS.
Co-expression of eNOS and CAV-1F92A enhances NO pro-
duction and osteogenic differentiation
Lentiviral vectors expressing eNOS and CAV-1F92A (mu-
tant) or CAV-1WT (wild-type) were co-expressed in
eASCs, eASCeNOS+CAV-1F92A, and eASCeNOS+CAV-1WT, re-
spectively. Co-expression of eNOS and CAV-1F92A pro-
moted osteogenesis as evident by Alizarin Red S staining
(Fig. 2b) and calcium deposition (Fig. 2d) compared to
eNOS alone (eASCeNOS), and NO levels were also sig-
nificantly increased in the eASCeNOS+CAV-1F92A (Fig. 2c).
Co-expression of eNOS with CAV-1WT in eASCs (eAS-
CeNOS+CAV-1WT) reduced NO production (Fig. 2c) and
also osteogenesis as evident by Alizarin Red staining
(Fig. 2b) and calcium deposition (Fig. 2d). Quantitative
real-time PCR analysis revealed that Runx2 (Fig. 2e) and
ALP (Fig. 2f ) were significantly upregulated in the
eASCeNOS+CAVF92A cultures and downregulated in the
eASCeNOS+CAV-1WT cultures as compared with the
eASCeNOS cultures (Fig. 2e and f).
Exogenous NO donor enhances osteogenesis of eASC in a
dose-dependent manner
To confirm the direct role of NO levels on eASC osteo-
genesis, we treated eASCs with a concentration range of
exogenous NO donor (NONOate; Sigma-Aldrich). Treat-
ment with exogenous NO donor promoted osteogenesis
from 5 μM to 15 μM but this was reduced with high con-
centrations of NO donor (20 μM) as evident by Alizarin
Red staining (Fig. 4a). NONOate treatment also resulted
in a dose-dependent increase in Runx2 (Fig. 4b) and ALP
(Fig. 4c) gene expression, in which maximum levels of
both were achieved with 15 μM NONOate; notably, sig-
nificantly lower levels of Runx2 and ALP expression were
observed with 20 μM NO donor treatment.
Fig. 1 Immunofluorescence localization of eNOS, CAV-1F92A, and CAV-1WT in lentiviral transduced eASCs and un-transduced cells. a Un-transduced eASCs
show no endogenous endothelial nitric oxide synthase (eNOS) expression. b eNOS-transduced eASCs (green) show strong cytoplasmic expression. c U
n-transduced eASCs show endogenous caveolin expression (red). dWild-type caveolin-1 (CAV-1WT)-transduced eASCs show significantly stronger expression.
When e eNOS, f mutated caveolin-1 (CAV-1F92A), and g CAV-1WT were transduced to eASCs using lentiviral vectors, eNOS showed cytoplasm localization
(red) whereas both the CAV-1F92A and CAV-1WT showed plasma membrane localization (green). h Confocal microscopy analysis of co-transduction of eASCs
with eNOS and CAV-1F92A resulted in cytoplasmic eNOS expression (red) and membrane localization of CAV-1F92A (green)
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NO promotes endogenous Runx2 expression in
differentiating eASCs
To monitor the effect of NO on endogenous Runx2
expression in differentiating eASCs, we generated a GFP
lentiviral reporter system under the control of a Runx2
enhancer fused to the Hsp68 promoter (Runx2.Hsp68-
eGFP; Fig. 5a) based on a novel Runx2 enhancer. eASCs
which were stably transduced with the Runx2 reporter
Fig. 2 Nitric oxide promotes osteogenic differentiation of eASCs. a Schematic of lentiviral transduction and osteogenic induction strategy. b Alizarin Red S
staining after 11 days in osteogenic induction medium or growth medium. c Nitric oxide release from cells undergoing osteogenic differentiation through
quantification of nitrite by Greiss assay. d Quantification of calcium deposition. Relative mRNA transcripts analysis by qPCR of e Runx2 and f alkaline phosphtase
(ALP) osteoblast markers showing increased expressions in endothelial nitric oxide synthase (eNOS) and eNOS+mutated caveolin-1 (eNOS+CAV-1F92A) transduced
cells compared to all other treatments. *p<0.05, versus eNOS+CAV-1WT, CAV-1WT, CAV-1F92A, eASC (osteogenic induction), eASC (growth medium). ; #p<0.05
versus eNOS, eNOS+CAV-1WT, CAV-1WT, CAV-1F92A, eASC (osteogenic induction), eASC (growth medium).CAV-1WT wild-type caveolin-1
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showed low levels of GFP expression in mostly undiffer-
entiated cells (Fig. 5b), whereas GFP expression as a re-
sult of Runx2 promoter activity in differentiating eASCs
was increased (Fig. 5b). When eASCs were transduced
with eNOS (eASCeNOS), the GFP signals were increased
compared to eASCs co-transduced with eNOS and CAV-
1WT (eASCeNOS+CAV-1WT) and un-transduced control
(eASCWT) (Fig. 5b). Interestingly, we observed that en-
dogenous Runx2 activity was remarkably increased when
the eASCs were co-transduced with eNOS and CAV-1F92A
(eASCeNOS+CAV-1F92A) (Fig. 5b) compared to eASCeNOS,
eASCeNOS+CAV-1WT, and eASCWT. Osteogenic nodule
Fig. 3 Inhibition of endothelial nitric oxide synthase (eNOS) through L-NG-nitroarginine methyl ester (L-NAME) treatment downregulates eASC
osteogenic differentiation. Relative mRNA transcripts analysis by qPCR showing that 2 mM L-NAME treatment decreased the expression of osteoblast
markers a alkaline phosphatase (ALP) and b Runx2 in eNOS transduced eASCs compared to untreated eNOS transduced cells. *p < 0.05, versus eNOS
(L-NAME), eASC (osteogenic induction), and eASC (growth medium)
Fig. 4 The exogenous nitric oxide donor NONOate promotes osteogenic differentiation in a dose-dependent manner. a Alizarin Red S staining of
eASCs after 11 days in osteogenic induction medium or growth medium. Relative mRNA transcript analysis shows a significant increase of osteoblast
markers b Runx2 and c alkaline phosphatase (ALP) when the eASCs were treated with 15 μM NONOate. *p < 0.05, versus 0 μM, 5 μM, 10 μM, and
20 μM NONOate, and control (growth medium)
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formation was significantly increased in the eASCeNOS
+CAV-1F92A (Fig. 5c), and these result suggests that en-
dogenous Runx2 expression is less active in undifferenti-
ated eASCs and its expression is significantly increased
through NO signaling during osteogenic differentiation.
NO modulates Wnt signaling to promote osteogenic
differentiation
To examine the role of canonical and non-canonical Wnt
signaling during NO-mediated osteogenic differentiation,
expression of Wnt3a, Wnt8a, and Wnt5a was assessed
by quantitative real-time PCR. Non-canonical Wnt5a
expression was reduced in eASCeNOS (Fig. 6c), and was sig-
nificantly further decreased in eASCeNOS+CAVF92A (Fig. 6c).
However, expression of canonical Wnt ligands Wnt3a
(Fig. 6a) and Wnt8a (Fig. 6b) was upregulated in eASCeNOS
and significantly further increased in eASCeNOS+CAVF92A
(Fig. 6a and b, respectively). Treatment with 2 mM L-
NAME showed downregulation of Wnt3a expression
(Fig. 6d) and upregulation of Wnt5a (Fig. 6e) in eASCeNOS,
indicating that NO modulates Wnt signaling pathway
in eASCs.
Furthermore, treatment with NO donor (NONOate)
also resulted in increased expression of canonical Wnt
ligands Wnt3a (Fig. 7a) and Wnt8a (Fig. 7b), and down-
regulation of non-canonical Wnt5a expression (Fig 7c) in
a dose-dependent manner from 5 μM to 15 μM of NON-
Oate. Interestingly, when the NO donor concentration
was increased up to 20 μM, the effect was completely re-
versed by downregulating Wnt3a (Fig. 7a) and Wnt8a
(Fig. 7b), and upregulating Wnt5a expression (Fig. 7c).
Control cells (eASCs in normal growth medium) also
showed increased expression of Wnt5a (Fig. 7c), suggest-
ing that induction of osteogenic differentiation of eASCs
requires activation of canonical Wnt signaling and sup-
pression of non-canonical Wnt5a expression.
To further analyze the relationship between NO-induced
osteogenic differentiation and Wnt signaling, eNOS-
transduced eASCs were treated with 20 ng/mL of the Wnt
signaling inhibitor, Dickkopf-related protein 1 (Dkk-1).
Dkk-1 treatment resulted in a significant downregulation of
the osteoblast specific markers ALP (Fig. 8a) and Runx2
(Fig. 8b) compared to untreated eNOS transduced cells.
Canonical Wnt3a promotes osteogenesis while non-
canonical Wnt5a suppresses osteogenesis
To explore the opposite effects of canonical and non-
canonical Wnt signaling pathways on eASC osteogenesis,
Fig. 5 Activity of a Runx2 reporter during eASC osteogenic differentiation. a Schematic of the Runx2.Hsp68-eGFP lentiviral reporter used to
transduce eASCs. The construct contains 343 bp of Runx2 enhancer and Hsp68 minimal promoter upstream to the enhanced green fluorescent
protein (eGFP). b Runx2 reporter containing eASCs were transduced with endothelial nitric oxide synthase (eNOS), eNOS +mutated caveolin-1
(eNOS + CAV-1F92A), and eNOS + wild-type caveolin-1 (eNOS + CAV-1WT) following osteogenic induction up to 11 days, and GFP signals were
detected by fluorescence microscopy and c increased numbers of osteogenic nodules were observed. *p < 0.05, versus eNOS, eNOS + CAV-1WT,
eASC (osteogenic induction), and eASC (growth medium). DMEM Dulbecco’s modified Eagle’s medium
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we generated canonical Wnt3a and non-canonical Wnt5a
expressing lentiviral vectors and transduced eASCs.
Wnt3a-transduced eASCs (eASCWnt3a) and Wnt5a-
transduced eASCs (eASCWnt5a) were incubated in osteo-
genic induction medium (OM) for 11 days. Interestingly,
we found that Wnt3a (eASCWnt3a) promoted osteogenesis
as evident by Alizarin Red staining compared to un-
transduced eASCs (eASCWT) (Fig. 9a). On the other hand,
overexpression of Wnt5a (eASCWnt5a) reduced osteogenic
differentiation (Fig. 9a). Quantitative analysis of the
mRNA levels by real-time PCR revealed that ALP (Fig. 9b)
and Runx2 (Fig. 9c) were upregulated in the eASCWnt3a
culture as compared with the ASCWT culture, and down-
regulated in eASCWnt5a culture, suggesting that lenitiviral
vector-mediated Wnt3a expression can promote osteo-
genesis while expression of non-canonical Wnt5a sup-
presses osteogenesis.
NO promotes the canonical Wnt signaling pathway by
promoting nuclear translocation of β-catenin
To further explore mechanisms by which NO promotes
canonical Wnt signaling, we used a lentiviral vector ex-
pressing GFP reporter under the control of the TCF/LEF
promoter (TOPFLASH; Addgene). In the canonical Wnt
signaling pathway, β-catenin translocation to the nucleus
is promoted by the activation of canonical Wnt signaling
[52, 53]. Accordingly, eASCs were introduced with the
lentiviral TCF/LEF-dGFP reporter, and those cells were
then co-transduced with doxycycline inducible eNOS
expressing lentiviral vector (Fig. 10a). As a readout for
nuclear translocation of β-catenin, the TCF/LEF-driven
GFP mRNA expression levels were measured by quan-
titative real-time PCR. Under osteogenic induction
conditions, increased GFP mRNA expression was
demonstrated compared to non-osteogenic induction
Fig. 7 Treatment with nitric oxide donor NONOate modulates Wnt signaling. Relative mRNA transcript analysis by qPCR shows that exogenous
NONOate treatment significantly upregulates the expression of canonical Wnt ligands a Wnt3a and b Wnt8a in a dose-dependent manner up to
15 μM with a corresponding downregulation of the non-canonical Wnt ligand c Wnt5a. *p < 0.05, versus 0 μM, 5 μM, 10 μM, 20 μM, and 0 μM
(growth medium)
Fig. 6 Nitric oxide signaling modulates Wnt signaling in eASCs. Relative mRNA transcript analysis by qPCR shows that endothelial nitric oxide synthase
(eNOS) and eNOS +mutated caveolin-1 (eNOS + CAV-1F92A) transduced cells increased the expression of canonical Wnt ligands a Wnt3a and bWnt8a, whilst
downregulating c non-canonical Wnt5a. Relative mRNA transcripts analysis by qPCR shows that treatment with 2 mM L-NG-nitroarginine methyl ester
(L-NAME) downregulated d Wnt 3a and upregulated e Wnt5a expression. *p< 0.05 eNOS+CAV-1WT, CAV-1WT, CAV-1F92A, eASC (osteogenic induction),
eASC (growth medium). and #p< 0.05 versus eNOS +wild-type caveolin-1 (CAV-1WT), CAV-1WT, CAV-1F92A, eASC (osteogenic induction), and eASC (in
DMEM); ##p< 0.05, versus eNOS (L-NAME) eASC (osteogenic induction) and eASC (growth medium)
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conditions (cells in growth medium) (Fig. 10b). When
doxycycline was added to the OM, GFP mRNA ex-
pression was significantly increased in the eNOS-
transduced cells (eASCeNOS) (Fig. 10b). Interestingly,
when doxycycline was removed from the medium,
GFP mRNA expression in eASCeNOS was similar to
other osteogenic induction conditions (Fig. 10b).
Using a β-catenin-specific monoclonal antibody, we fur-
ther investigated the effect of NO on β-catenin nuclear
translocation. eASCs were transduced with the doxycycline
Fig. 8 Inhibition of Wnt signaling through Dickkopf-related protein 1 (Dkk-1) downregulates eASC osteogenic differentiation. Relative mRNA transcript
analysis by qPCR shows that Dkk-1 treatment (20 ng/mL) decreased the expression of osteoblast markers a alkaline phosphatase (ALP) and b Runx2 in
endothelial nitric oxide synthase (eNOS)-transduced eASCs compared to untreated eNOS-transduced eASCs. *p < 0.05, versus eNOS (Dkk-1), eASC
(osteogenic induction with Dkk-1), eASC (osteogenic induction), and eASC (growth medium)
Fig. 9 Lentiviral expression of canonical Wnt3a promotes osteogenesis and non-canonical Wnt5a results in suppressed osteogenesiss. a Alizarin
Red S staining after 11 days in osteogenic induction medium or growth medium showing that lentiviral Wnt3a transduction increased the calcium
deposition, whereas Wnt5a decreased calcium deposition levels. Relative mRNA transcript analysis by qPCR showing that Wnt3a upregulates the
expression of osteoblast markers b alkaline phosphatase (ALP) and c Runx2 expression, whereas Wnt5a resulted in downregulation. *p < 0.05, versus
Wnt5a, eASC (osteogenic induction), and eASC (growth medium)
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inducible eNOS lentiviral vector followed by immunostain-
ing with β-catenin-specific monoclonal antibody (Cell
Signaling Technology). When doxycycline was added to the
OM, the expression of β-catenin was observed in eNOS-
transduced cells (eASCeNOS) (Fig. 11a) in both the nucleus
and cytoplasm, and when doxycycline was removed from
the medium β-catenin expression in eASCeNOS was reduced
(Fig. 11a) to that seen in un-transduced control cells
(Fig. 11a). Furthermore, we observed nuclear co-localization
of β-catenin and DAPI only in doxycycline-treated eASCeNOS
suggesting that NO may promote nuclear localization of β-
catenin (Fig. 11b). As a control for the primary antibody, im-
munostaining was carried out in the absence of the primary
antibody specific to β-catenin (Additional file 2: Figure S2).
Together, these findings support the paradigm that
cellular environments rich in bioavailable NO through
either genetic modification or exogenous sources can
modulate Wnt signaling, by upregulating the canonical
and downregulating the non-canonical pathways result-
ing in increased osteogenic differentiation (Fig. 12).
Discussion
NO plays an important role in osteogensis, bone remodel-
ing, and metabolism [54–56]. It has been reported that
both iNOS and eNOS play a role in osteogenesis of
embryonic stem cells [57]. We [4] and others [58] have
shown that MSCs do not express eNOS. Therefore, in
order to investigate the role of eNOS in osteogenic differen-
tiation of eASCs, in this study eASCs were genetically
modified by lentiviral vector-based eNOS. ASCs are prom-
ising candidates for stem cell-based therapy for bone repair
[59], and the role of eNOS-mediated NO synthesis and its
downstream effect on osteogenesis of MSCs remains to be
explored. We found that eNOS gene transfer by lentiviral
vector promoted osteoblast-specific gene expressions
(Fig. 2e and f), contributing to the matrix mineralization as
visualized by Alizarin Red S staining (Fig. 2b and d). Note-
worthy, this osteogenic potential of eASCseNOS was signifi-
cantly abrogated by L-NAME treatment (Fig. 3), suggesting
that NO derived from eNOS plays a major role in enhan-
cing osteogenesis in eASCs.
CAV-1 is a key negative regulator of eNOS activation and
thus inhibits the production of NO [41, 60] and, import-
antly, CAV-1 is expressed endogenously in MSCs [61]. The
scaffolding domain (82-101 amino acids) of CAV-1 protein
interacts with eNOS at the plasma membrane and this inter-
action inhibits the eNOS activation reducing NO synthesis
[41]. An alanine scanning approach revealed that substitu-
tion of phenylalanine at the amino acid position 92 with
alanine to produce CAV-1F92A mutant restored the eNOS
Fig. 10 Nitric oxide signaling promotes activity of a β-catenin reporter. a Schematic of lentiviral transduction of a β-catenin reporter, TCF/LEF
(TOP-dGFP), and a doxycycline (DOX) inducible endothelial nitric oxide synthase (eNOS) transduction and assessment of TCF/LEF activity during
osteogenesis. b Relative mRNA transcript analysis by qPCR showing eNOS upregulates GFP mRNA expression when treated with DOX. *p < 0.05,
versus TOP-dGFP + eNOS (no DOX), TOP-dGFP (osteogenic induction), TOP-dGFP (growth medium), and un-transduced eASC (growth medium)
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Fig. 12 Proposed signaling mechanism underlying osteogenic differentiation induced by NO in eASCs. Molecular control of NO levels may
activate and suppress the expression of endogenous canonical and non-canonical Wnt ligands, respectively, to promote nuclear localization
of β-catenin and subsequent activation of osteogenic differentiation through promoting osteoblast-specific gene transcription. CAV-1F92A
mutated caveolin-1, CAV-1WT wild-type caveolin-1, eNOS endothelial nitric oxide synthase
Fig. 11 Nitric oxide promotes nuclear translocation of β-catenin. a Immunostaining with a β-catenin-specific monoclonal antibody reveals that
the expression of β-catenin in endothelial nitric oxide synthase (eNOS) transduced cells when doxycycline (DOX) is available in the medium.
b nuclear localization of beta catenin in eNOS transduced cells in DOX containing medium. Arrows indicate nuclear localisation of β-catenin
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activation and promoted NO synthesis [41]. Thus, in order
to understand the contribution of caveolin-1 on the control
of NO synthesis in eASC osteogenesis, we modified eASCs
by expressing CAV-1WT (as a negative regulator for eNOS
activation) or CAV-1F92A (as a positive regulator for eNOS
activation) together with eNOS. Confirming a previous
observation [41], we found that co-expression of eNOS and
CAV-1F92A increased NO production while eNOS and
CAV-1WTco-expressed eASCs showed reduced NO produc-
tion (Fig. 2c), suggesting that CAV-1 is an important regula-
tor of NO production in eASCs. We further found that
these controlled levels of NO synthesis regulate osteogen-
esis, where eNOS together with CAV-1F92A resulted in in-
creased osteogenic differentiation of eASCs.
To explore the molecular basis of NO-mediated osteo-
genesis, we investigated the effect of NO on Wnt signal-
ing. Wnt signaling pathways have been shown to regulate
osteoblastogenesis [62], in which canonical Wnt ligands
promote osteogenesis [63, 64], and non-canonical Wnt5a
can inhibit the canonical Wnt signaling [65]. In the ca-
nonical Wnt pathway, binding of canonical Wnt ligands
such as Wnt3a and Wnt8a to cell surface frizzled recep-
tors results in the nuclear translocation of β-catenin [66],
which ultimately binds with the TCF/LEF region to initiate
the transcription of osteogenic genes such as Runx2 [62].
On the other hand, binding of non-canonical Wnt5a lig-
and to the ROR2 member of the Ror-family of RTKs in-
hibits canonical Wnt signaling by promoting β-catenin
degradation, and downregulation of β-catenin reduced
osteoblast-specific gene expression [67]. Our results re-
vealed that genetic manipulation of eASCs with eNOS
and CAV-1F92A (eASCeNOS+CAV-1F92A) increased canonical
Wnt3a and Wnt8a expression, whereas eASCeNOS+CAV-
1WT decreased Wnt3a and Wnt8a expression (Fig. 6a and
b), suggesting that NO levels may regulate Wnt ligand ex-
pression and promote osteogenesis. Confirming the role
of Wnt signaling on osteogenesis, inhibition of canonical
Wnt signaling through Dkk-1 treatment of eNOS-
expressing cells attenuated osteogenesis as evident by
downregulation of osteoblast-specific Runx2 and ALP ex-
pression (Fig. 8). On the other hand, the effect of non-
canonical Wnt5a expression was completely the opposite
(Fig. 6c) to the canonical Wnt3a and Wnt8a expression
profiles, suggesting that molecular control of NO synthe-
sis through eNOS/CAV-1 interaction or exogenous NO
treatment (Fig. 7) results in differential regulation of Wnt
ligand expression and their subsequent effect on osteo-
genic differentiation. Furthermore, we also found that NO
modulates Wnt signaling and promotes osteogenesis
when a differentiation environment is enhanced with an
optimum concentration of exogenous NO (Figs. 4 and 7).
It has been shown that Wnt3a can directly promote
osteogenesis [68], whilst Wnt5a plays a role in self-
renewal of stem cells [69]. We further investigated the
direct effect of canonical Wnt3a and non-canonical
Wnt5a on eASC osteogenesis through lentiviral vector
overexpression. Interestingly, corroborating our results on
NO-mediated Wnt-regulated osteogenesis, Wnt3a pro-
moted osteogenesis (Fig. 9a–c) whereas Wnt5a inhibited
osteogenesis (Fig. 9a–c). It was shown that increased levels
of β-catenin can promote bone formation through
increasing the expression of osteoblast-specific genes
[70, 71], whilst abnormal osteoblast differentiation has
been observed with β-catenin knockdown [70, 72]. Thus,
it is possible that Wnt3a promotes osteogenesis by in-
creasing β-catenin stability and Wnt5a may suppress
osteogenesis by degrading β-catenin. NO may regulate
this mechanism by increasing Wnt3a and suppressing
Wnt5a ligand availability to modulate nuclear localization
of β-catenin via the canonical Wnt ligand transduction
pathway. In support of this, we observed that eNOS-
transduced cells promoted the expression of β-catenin
and its nuclear localization (Fig. 11), and a TCF/LEF-dGFP
reporter assay demonstrated responsiveness in a NO-rich
cellular environment (Fig. 10b), which could be controlled
through the expression of DOX-inducible eNOS.
Conclusions
In summary, our findings provide an insight into the
role of NO in promoting eASC osteogenic differentiation
in a cellular environment of optimum levels of NO
through interaction with Wnt signaling pathways. This
may lead to the development of novel cell-based thera-
peutic approaches for bone repair, in particular in vitro
modification of MSCs by NO to optimize the endogen-
ous Wnt signaling pathway to promote osteogenic differ-
entiation upon subsequent transplantation.
Additional files
Additional file 1: Figure S1. Primary antibody controls for Fig. 1.
As a control for specific primary antibody binding, immunostaining was
performed in the absence of primary antibodies, with only fluorophore
tagged secondary antibody present. We confirm no florescence signal
was detected these controls for eNOS and CAV-1. (a) Detection of nuclear
staining by Dapi and (b) immunostaining performed without mouse
monoclonal anti-eNOS antibody but with an anti-mouse IgG secondary
antibody conjugated with Alexa 488. (c) Detection of nuclear staining by
Dapi and (d) immunostaining performed without rabbit polyclonal anti-
CAV-1 antibody but with an anti-rabbit IgG secondary antibody conju-
gated with Alexa 555. (e) Detection of nuclear staining by Dapi and (d)
fluorescence detection with no mouse monoclonal anti-eNOS antibody
with an anti-mouse IgG secondary antibody conjugated with Alexa 555.
(f) Detection of nuclear staining by Dapi and (g) fluorescence detection
with no rabbit polyclonal anti-CAV-1 antibody with an anti-rabbit IgG
secondary antibody conjugated with Alexa 488. (PPT 182 kb)
Additional file 2: Figure S2. Primary antibody controls for Fig. 11. As a
control for specific β-catenin primary antibody binding, immunostaining was
carried out in the absence of the primary antibody with no florescence signal
detected. (a) Detection of nuclear staining by Dapi and (b) fluorescence
detection without rabbit monoclonal anti-β-catenin antibody with an anti-
mouse IgG secondary antibody conjugated with Alexa 488. (PPT 102 kb)
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